FI97777B - Förfarande för framställning av sammansättning för ögondroppar - Google Patents

Förfarande för framställning av sammansättning för ögondroppar

Info

Publication number
FI97777B
FI97777B FI913811A FI913811A FI97777B FI 97777 B FI97777 B FI 97777B FI 913811 A FI913811 A FI 913811A FI 913811 A FI913811 A FI 913811A FI 97777 B FI97777 B FI 97777B
Authority
FI
Finland
Prior art keywords
preparation
eye drop
drop composition
composition
benzoxadine
Prior art date
Application number
FI913811A
Other languages
English (en)
Finnish (fi)
Other versions
FI913811A0 (sv
FI913811A (sv
FI97777C (sv
Inventor
Kazumichi Ushio
Yoshifumi Ikejiri
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Publication of FI913811A0 publication Critical patent/FI913811A0/sv
Publication of FI913811A publication Critical patent/FI913811A/sv
Application granted granted Critical
Publication of FI97777B publication Critical patent/FI97777B/sv
Publication of FI97777C publication Critical patent/FI97777C/sv

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
FI913811A 1990-08-13 1991-08-12 Förfarande för framställning av sammansättning för ögondroppar FI97777C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP21482790 1990-08-13
JP21482790 1990-08-13
JP16285491 1991-07-03
JP16285491 1991-07-03

Publications (4)

Publication Number Publication Date
FI913811A0 FI913811A0 (sv) 1991-08-12
FI913811A FI913811A (sv) 1992-02-14
FI97777B true FI97777B (sv) 1996-11-15
FI97777C FI97777C (sv) 1997-02-25

Family

ID=26488494

Family Applications (1)

Application Number Title Priority Date Filing Date
FI913811A FI97777C (sv) 1990-08-13 1991-08-12 Förfarande för framställning av sammansättning för ögondroppar

Country Status (16)

Country Link
US (1) US5663170A (sv)
EP (1) EP0472327B1 (sv)
JP (1) JP2769253B2 (sv)
KR (1) KR920003971A (sv)
AT (1) ATE121295T1 (sv)
AU (1) AU633754B2 (sv)
CA (1) CA2048942A1 (sv)
DE (1) DE69109021T2 (sv)
DK (1) DK0472327T3 (sv)
ES (1) ES2071227T3 (sv)
FI (1) FI97777C (sv)
HU (1) HU207950B (sv)
NO (1) NO177845C (sv)
PT (1) PT98643B (sv)
RU (1) RU2068260C1 (sv)
TW (1) TW200402B (sv)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK143893A3 (en) * 1992-03-18 1994-05-11 Cooper Vision Pharmaceuticals Verapamil hci formulation and other opthalmic solutions with buffer system for ocular administration
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
WO1994010976A1 (en) * 1992-11-16 1994-05-26 Ciba Vision Ag, Hettlingen Polyvinyl alcohol/borate ophthalmic drug delivery system
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
SE501482C2 (sv) * 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
CA2165299A1 (en) * 1993-07-28 1995-02-09 Lyle M. Bowman Suspensions for delivery of medicament
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
WO1996001558A1 (en) * 1994-07-11 1996-01-25 Pate David W Anandamide analogue compositions and method of treating intraocular hypertention using same
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
JP3672569B2 (ja) * 1995-01-20 2005-07-20 わかもと製薬株式会社 抗炎症点眼剤
HUT77445A (hu) * 1995-01-20 1998-04-28 Wakamoto Pharmaceutical Co. Ltd. Gyulladásgátló szemcsepp
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
JP2001125052A (ja) * 1999-10-25 2001-05-11 Lion Corp コンタクトレンズ装着液
ES2263623T3 (es) * 2000-06-19 2006-12-16 Santen Pharmaceutical Co., Ltd. Agentes antisepticos.
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
JPWO2006137433A1 (ja) * 2005-06-21 2009-01-22 わかもと製薬株式会社 レボカバスチンを可溶化させた水性薬剤
US20100069335A1 (en) * 2005-07-15 2010-03-18 Rajiv Bhushan Prevention and Treatment of Ophthalmic Complications of Diabetes
MX353874B (es) 2012-03-26 2018-02-01 Santen Pharmaceutical Co Ltd Gotas para los ojos que contienen diquafosol.
TW202014194A (zh) * 2018-04-27 2020-04-16 美商歐樂根公司 抗微生物功效增強且毒性降低之亞氯酸鈉組成物
EP4052694A4 (en) * 2019-11-21 2023-09-20 Samjin Pharmaceutical Co., Ltd. EYE DROPS COMPOSITION FOR PREVENTING OR TREATING EYE DISEASES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602641B2 (en) * 1986-04-17 1990-10-18 Senju Pharmaceutical Co., Ltd. Thiolactam-N-acetic acid derivatives, their production and use

Also Published As

Publication number Publication date
US5663170A (en) 1997-09-02
NO913136D0 (no) 1991-08-12
AU8170891A (en) 1992-02-20
PT98643B (pt) 1999-01-29
ATE121295T1 (de) 1995-05-15
NO177845C (no) 1995-12-06
FI913811A0 (sv) 1991-08-12
RU2068260C1 (ru) 1996-10-27
JPH05213757A (ja) 1993-08-24
TW200402B (sv) 1993-02-21
NO913136L (no) 1992-02-14
CA2048942A1 (en) 1992-02-14
DE69109021T2 (de) 1995-09-21
EP0472327A1 (en) 1992-02-26
JP2769253B2 (ja) 1998-06-25
DK0472327T3 (da) 1995-05-08
PT98643A (pt) 1992-07-31
EP0472327B1 (en) 1995-04-19
AU633754B2 (en) 1993-02-04
ES2071227T3 (es) 1995-06-16
HUT61196A (en) 1992-12-28
FI913811A (sv) 1992-02-14
NO177845B (no) 1995-08-28
HU207950B (en) 1993-07-28
FI97777C (sv) 1997-02-25
KR920003971A (ko) 1992-03-27
DE69109021D1 (de) 1995-05-24
HU912692D0 (en) 1992-01-28

Similar Documents

Publication Publication Date Title
FI97777B (sv) Förfarande för framställning av sammansättning för ögondroppar
EP0270362A3 (en) Pyridinylpyrimidine derivatives, method for production thereof and a fungicide containing them as the active ingredient
NO179518C (no) AnalogifremgangsmÕte for fremstilling av 2- hydroksymetylcytosin-substituerte 1,3-oksatiolaner
AU7815791A (en) Heterocyclene derivatives
AU1331588A (en) Method for treatment of alcohol abuse
DE59405376D1 (de) Eintopfverfahren zur Herstellung von 3-Chinoloncarbonsäurederivaten
DE69124769T2 (de) Verfahren zur Herstellung von (1'R,3S)-3-(1'-hydroxy-ethyl)-Azetidin-2-on und deren Derivaten
NO179612C (no) Analogifremgangsmåte for fremstilling av 3-arylkarbonyl-1-aminoalkyl-1H-indol-forbindelser
FI98703B (sv) Förfarande för framställning av ett hirudinderivat
NO301767B1 (no) Salt av clavulansyre
NO176098C (no) Analogifremgangsmåte for fremstilling av 2-substituerte N,N'-ditrimetoksybenzoyl-piperaziner
AU2706788A (en) Method of inhibiting virus
FI900145A0 (sv) Förfarande för framställning av farmaceutiskt användbara 1,1-dioxo-cefem-4-karbotiolsyraderivat
NO883520L (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
DE68923159D1 (de) Verfahren zur Herstellung von 1,4-Dihydropyridin-Derivaten.
DE69720496D1 (en) Benzimidazolderivate
FI891111A0 (sv) Förfarande för framställning av 1,4-dihydropyridinderivat
AU5494290A (en) Antirhinoviral pyridazinamines
DE59105920D1 (de) Verfahren zur Herstellung von 5-Hydroxy-3,4,5,6-tetrahydro-pyrimidin-Derivaten.
ATE126190T1 (de) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-
DE68920493T2 (de) Verfahren zur Herstellung von Derivaten von 2'-Deoxy-beta-cytidin und Salze davon.
AU575067B2 (en) Salts of l or (s)-3-(3,4-dihydroxyphenyl)-2- methylalanine esters
WO1994012483A3 (de) Thiocyanatomethylthiobenzthiazol-derivate

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed